Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:China
|
| gptkbp:ATCCode |
C10AX18
|
| gptkbp:CASNumber |
2417897-97-7
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Innovent_Biologics
|
| gptkbp:mechanismOfAction |
PCSK9 inhibitor
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
gptkb:PCSK9
|
| gptkbp:usedFor |
gptkb:familial_hypercholesterolemia
|
| gptkbp:bfsParent |
gptkb:PCSK9_protein
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
tafolecimab
|